文献速递血栓与止血

重组人血小板生成素治疗儿童及青少年慢性原发性免疫性血小板减少症的有效性与安全性:多中心、随机、双盲、安慰剂对照III期试验

Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double-blind, placebo-controlled phase III trial.
PubMed 文献 · Br J Haematol · 2024-09-12

本研究为多中心随机双盲安慰剂对照III期试验,纳入6-17岁对糖皮质激素耐药或复发的慢性原发免疫性血小板减少症患者68例。Part 1探索年龄分层,Part 2按3:1随机接受rhTPO 300 U/kg每日一次最多14天或安慰剂。Part 2中rhTPO组总缓解率58.5% vs 安慰剂组13.3%(FAS),差异45.2%(95%CI 22.33%-68.08%),PPS差异44.6%(95%CI 21.27%-67.85%),提示rhTPO优效。

要点

  • Part 2中rhTPO组总缓解率58.5%(95%CI 42.11%-73.68%) vs 安慰剂组13.3%(95%CI 1.66%-40.46%)(FAS)。
  • FAS中两组总缓解率差异45.2%(95%CI 22.33%-68.08%),PPS差异44.6%(95%CI 21.27%-67.85%)。
  • Part 1总缓解率为50.0%(95%CI 21.09%-78.91%)。

核心结论

  • 在6-17岁对糖皮质激素耐药或复发的慢性原发免疫性血小板减少症患者中,rhTPO治疗较安慰剂显示优效性。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照III期试验,纳入6-17岁诊断ITP且对糖皮质激素耐药或复发的患者。
  • Part 1为探索性部分,确定Part 2是否按年龄分层,患者按6-11岁/12-17岁组1:1接受rhTPO。
  • Part 2为主要分析,患者按3:1随机接受rhTPO或安慰剂,剂量300 U/kg每日一次,最多14天。
  • 共纳入68例患者,Part 1为12例,Part 2为56例。

主要发现

  • Part 1总缓解率为50.0%(95%CI 21.09%-78.91%)。
  • Part 2中rhTPO组总缓解率为58.5%(95%CI 42.11%-73.68%),安慰剂组为13.3%(95%CI 1.66%-40.46%)(FAS)。
  • Part 2中rhTPO组与安慰剂组总缓解率差异在FAS为45.2%(95%CI 22.33%-68.08%),在PPS为44.6%(95%CI 21.27%-67.85%)。

关键数值与推荐

  • rhTPO或安慰剂剂量为300 U/kg,每日一次,最多14天。
  • Part 2随机比例为3:1(rhTPO:安慰剂)。
  • 总缓解率差异FAS为45.2%(95%CI 22.33%-68.08%),PPS为44.6%(95%CI 21.27%-67.85%),提示rhTPO优效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The efficacy and safety of recombinant human thrombopoietin (rhTPO) in children and adolescent patients with chronic primary immune thrombocytopenia (ITP) remains unclear. A multicentre, randomized, double-blind, placebo-controlled phase III trial was performed. Patients aged 6-17 years, diagnosed with ITP and resistant or relapsed to corticosteroid treatment were included. For the trial, part 1 was exploratory and part 2 was the main analysis, with part 1 determining whether part 2 was stratified by age. Patients in part 1 were treated with rhTPO (the 6- to 11-/12- to 17-year-old groups; 1:1). Patients in part 2 were randomized (3:1) to receive either rhTPO treatment or placebo. Patients received rhTPO or placebo at a dose of 300 U/kg once daily for up to 14 days. A total of 68 patients were included [part 1 (12 patients), part 2 (56 patients)]. The total response rate (TRR) in part 1 was 50.0% (95% CI: 21.09%-78.91%). For part 2, the TRR was 58.5% (95% CI: 42.11%-73.68%) and 13.3% (95% CI: 1.66%-40.46%) in the rhTPO and placebo groups (FAS) respectively. The difference in TRR between the rhTPO group and placebo group was 45.2% (95% CI: 22.33%-68.08%) and 44.6% (95% CI: 21.27%-67.85%) on the FAS and per-protocol set (PPS), respectively, which indicates the superiority of rhTPO treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ma J, Zhang X, Zhao L, et al. Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double-blind, placebo-controlled phase III trial. Br J Haematol. 2024. PMID: 39267281. doi:10.1111/bjh.19761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。